Kolistimetatnatrium Noridem

Colistimethate Sodium, the active ingredient in Kolistimetatnatrium Noridem, is a Polymyxin antibiotic presented as an inhalation solution for inhalation use. It treats chronic lung infection caused by Pseudomonas aeruginosa in cystic fibrosis patients and is supplied under a prescription-only status in the EU market.

GNH USA supplies Kolistimetatnatrium Noridem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Colistimethate Sodium is used to target Gram‑negative bacterial infections of the respiratory tract, particularly in cystic fibrosis patients.

- Chronic lung infection in cystic fibrosis: reduces Pseudomonas aeruginosa bacterial load and helps preserve lung function. - Pseudomonas aeruginosa pulmonary infection: provides targeted antibacterial therapy via inhalation to improve respiratory outcomes.

Colistimethate Sodium may cause a range of adverse reactions, most of which are related to its local administration to the airways.

Common Side Effects: - Cough: irritation of the bronchial mucosa. - Bronchospasm: transient narrowing of airways. - Throat irritation or soreness. - Taste disturbance or metallic taste. - Nausea or mild gastrointestinal upset. - Headache.

Serious or Rare Side Effects: - Anaphylactic reaction: signs of severe allergy. - Respiratory distress: worsening of breathing difficulty. - Hemoptysis: coughing up blood. - Nephrotoxicity: impaired kidney function. - Ototoxicity: hearing loss or tinnitus. - Severe bronchospasm requiring medical intervention.

When prescribing or handling Colistimethate Sodium inhalation solution, several safety considerations are recommended.

- Renal function assessment: monitor kidney parameters due to potential nephrotoxicity. - Respiratory monitoring: observe for bronchospasm, especially in patients with reactive airway disease. - Hypersensitivity screening: avoid use in individuals with known allergy to polymyxins. - Pregnancy caution: safety not established; weigh benefits against potential risks. - Use in cystic fibrosis: ensure proper inhalation technique and adherence to therapy. - Store at room temperature: keep in original container, protect from moisture and light.

Colistimethate Sodium can interact with other medications, influencing safety and efficacy.

Major Interactions (Avoid): - Neuromuscular blocking agents: increased risk of respiratory paralysis. - Aminoglycosides: additive nephrotoxic effect. - Loop diuretics: heightened renal toxicity. - Other nephrotoxic drugs: cumulative kidney damage. - Polymyxin B: avoid concurrent use due to overlapping toxicity.

Moderate Interactions (Monitor Closely): - Carbapenem antibiotics: potential antagonism. - Inhaled bronchodilators: may mask bronchospasm. - Corticosteroids: monitor for enhanced infection risk.